Assurans (sildenafil) is generally used across two distinct therapeutic domains where symptomatic support is needed.

Supportive Management of Two Key Domains

Assurans is commonly used across conditions presenting with acute or episodic changes in sexual function, where a man experiences the inability to achieve or maintain a firm erection. The medication supports the ability to respond to sexual stimulation and is applied in clinical settings that involve recurrent or episodic manifestations of Erectile Dysfunction (ED). This use helps improve day-to-day comfort during symptomatic periods and assists with maintaining functional stability related to sexual health.

“The medication is generally applied to help ease the overall symptom burden that interferes with functional stability.”

The medication is also relevant in conditions involving episodic or fluctuating manifestations of increased physiological stress within the pulmonary arteries, specifically Pulmonary Arterial Hypertension (PAH). It is used for managing the related symptom cluster of shortness of breath and fatigue that interfere with daily functioning, especially during exertion. This long-term use may assist with managing symptoms and supports general well-being during symptomatic phases.

Quick Fact: Symptomatic Support Assurans is primarily used for Erectile Dysfunction and Pulmonary Arterial Hypertension, addressing symptoms that create noticeable functional strain in the domains of sexual health and physical capacity.

Regulatory References

1. NIH MedlinePlus Drug Information

Assurans (sildenafil) eligibility is strictly defined by government regulatory documents based on the patient's existing health conditions and concurrent medications.

Contraindicated Populations (Must Not Use)

• Patients using organic nitrates or nitric oxide donors (e.g., nitroglycerin) due to the risk of severe, life-threatening hypotension.
• Patients taking riociguat (a guanylate cyclase stimulator).
• Individuals with a history of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) in one eye.
• Patients with severe hepatic impairment (Child-Pugh Class C), recent stroke or myocardial infarction, or severe hypotension (BP <90/50 mmHg).

Age and Condition-Based Restrictions

Population Group	Eligibility Status (Regulatory Wording)
Adults (ED Indication)	Approved for use in adult men (ge 18 years). Not indicated for women.
Pediatric Patients (PAH Indication)	Approved for children ge 1 year in some regions, but chronic use is not recommended with increasing dose due to observed mortality risk.
Severe Renal/Hepatic Impairment	Use is permitted, but lower initial doses are advised for the ED indication due to reduced clearance.
Pregnancy/Lactation	Not recommended for PAH due to lacking safety studies. Not indicated for women for the ED indication.

Use is not recommended for patients with Pulmonary Veno-Occlusive Disease (PVOD) or known hereditary degenerative retinal disorders. Caution is advised for patients with conditions predisposing to priapism (e.g., sickle cell anemia) or anatomical penile deformation.

Interactions with other medicines and products

Official government regulatory documents classify interactions with Assurans (Sildenafil) based on two primary mechanisms: pharmacodynamic potentiation and pharmacokinetic metabolic alteration.

Formal Contraindications

The co-administration of Sildenafil with nitric oxide donors (including organic nitrates in any form) or Guanylate Cyclase (GC) Stimulators (such as riociguat) is contraindicated due to the officially documented risk of severe, life-threatening hypotension.

Documented Pharmacokinetic Interactions

Sildenafil is cleared predominantly by the CYP3A4 enzyme. Agents that inhibit this enzyme, such as Ritonavir, significantly increase Sildenafil's plasma concentration; for instance, Ritonavir is documented to increase the drug's exposure by approximately 11-fold. Conversely, potent CYP3A4 inducers, such as Bosentan, accelerate Sildenafil clearance and cause a substantial decrease in its plasma levels.

Other Significant Interactions

The official label notes that co-administration with alpha-blockers may lead to an additive hypotensive effect. To manage the high exposure risk with strong inhibitors, the regulatory label imposes a maximum dose restriction of 25 mg of Sildenafil within a 48-hour period when used with Ritonavir. Furthermore, Sildenafil absorption is reduced and delayed when taken with a high-fat meal.

The mechanism of Assurans (Sildenafil) is a specific intervention that preserves the signal for smooth muscle relaxation, resulting in vasodilation in targeted circulatory areas.

Selective Inhibition of the PDE5 Enzyme

Sildenafil functions as a highly selective competitive inhibitor of the enzyme Phosphodiesterase type 5 (PDE5), which is predominantly located in vascular smooth muscle cells. This action interrupts the natural degradation process, which is the key mechanistic step for preventing the enzymatic hydrolysis of cGMP.

Amplification of the NO/cGMP Signaling Cascade

By blocking PDE5, the drug prevents the rapid breakdown of the second messenger cyclic Guanosine Monophosphate (cGMP), causing its local concentration to increase. This sustained accumulation of cGMP activates downstream cellular effectors, which is the causal cascade that leads directly to a decrease in vascular smooth muscle tone.

Resulting Vascular Smooth Muscle Relaxation

The final step in the mechanism involves the tissue-level consequence of cellular relaxation, specifically the widening of the blood vessel lumen (vasodilation). This physiological adjustment reduces local vascular resistance and results in the increase of localized blood perfusion in the affected circulatory beds.

Official Administration Guidelines for Sildenafil (Assurans)

The usage protocol for sildenafil is defined by the medicine's indication, with distinct administration rules for Erectile Dysfunction (ED) and Pulmonary Arterial Hypertension (PAH).

---

Usage Parameter	ED Indication (As Needed)	PAH Indication (Continuous)
Route of Administration	Oral tablet, with or without food.	Oral tablet/suspension or Intravenous (IV) injection.
Standard Adult Dosing	Starting dose is 50 mg. The dose range is 25 mg to a maximum of 100 mg.	Recommended oral dose is 20 mg. Dose may be titrated up to a maximum of 80 mg t.i.d.
Dosing Frequency & Timing	Once per day maximum. Take approximately one hour before activity (range: 30 minutes to 4 hours).	Three times a day (t.i.d.), with doses spaced approximately 4 to 6 hours apart.

---

Procedural and Population-Specific Rules

Standard prescribing information outlines specific requirements for proper use and administration, regardless of the indication:

• Tablet Intake: Tablets may be taken with or without food. They must be swallowed whole and should not be crushed or chewed.
• Suspension Preparation: If using the oral suspension, the powder must be reconstituted and measured with a calibrated dosing device after shaking well.
• Special Population Dosing: For the ED indication, a lower starting dose of 25 mg should be considered for adults aged 65 years and older or those with severe renal or hepatic impairment.
• Missed Dose: For the continuous PAH regimen, a patient should take a missed dose as soon as possible, but must not double the dose to compensate.

Research Evidence / Overview of Studies for Assurans (Sildenafil)

Research for Assurans (Sildenafil) has been conducted primarily through formal clinical trials, including randomized studies that compare the drug against an inactive substance (placebo), and long-term studies that observe participants over extended periods. This overview summarizes what was observed in the research and what questions remain unanswered, based on official regulatory and scientific literature.

Evidence for Use in Erectile Dysfunction (ED)

Sildenafil was evaluated in short-term, randomized, double-blind, placebo-controlled trials for conditions characterized by episodic or acute changes in sexual function. These studies research examined a broad group of adult men with varying causes of Erectile Dysfunction. Studies monitored changes in functional measures, and results often described higher mean scores (IIEF domains) in the Sildenafil groups compared to participants who received a placebo. Furthermore, research highlights that in the studies, patients in the Sildenafil groups often reported higher rates of successful intercourse attempts compared to those receiving a placebo. However, data for certain groups remain insufficient, and comparative evidence is lacking for many head-to-head trials.

---

Evidence for Use in Pulmonary Arterial Hypertension (PAH)

Sildenafil was studied for use in Pulmonary Arterial Hypertension (PAH), a condition marked by functional limitations and high physiological strain in the lungs. The research base includes controlled trials that was evaluated in adults and children and adolescents. The primary outcomes related to systemic or functional imbalance that were measured included changes in activity level (6-minute walk distance) and time to clinical worsening, a combined measure of disease progression, hospitalization, or death. The trials data show patterns related to participants who used Sildenafil achieving a greater change in their 6-minute walk distance compared to the placebo groups after the initial short-term assessment. Studies also described how symptoms evolved in the observed populations, tracking a longer median time before the occurrence of a clinical worsening event for the Sildenafil groups compared to the placebo groups.

---

Research Gaps and What Remains Uncertain

The initial randomized controlled trials for PAH were not designed to collect data for definitive conclusions on all-cause mortality over the short-term duration of the core studies. Therefore, certainty remains low in this specific area based on the initial trial reports. For the pediatric population, findings were mixed when assessing the effects of different doses; regulatory concerns arose from observations in these long-term studies due to documented regulatory concerns arising from study observations. For all patient groups, data spanning decades of chronic use are not yet available, and long-term effects are not fully established.

Key Studies & References

1. A Randomized, Double-Blind, Placebo-Controlled Study of Sildenafil in Children With Pulmonary Arterial Hypertension (The STARTS trial - evidence for pediatric use and mixed results)
2. Label: SILDENAFIL tablet, film coated (FDA-approved label for Sildenafil 20mg for PAH, discussing regulatory changes and warnings)

The storage and disposal of Assurans (Sildenafil) must adhere strictly to the conditions defined in the regulatory labeling to maintain product integrity and ensure safety.

Official Storage Requirements

Condition Category	Regulatory Requirement Statement
Temperature	Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Do not freeze.
Protection	Protect the tablets from moisture and excessive heat. Keep the container tightly closed and in its original packaging.
Child Safety	Keep out of the sight and reach of children and pets, as required for all prescription medications.

Disposal Instructions

Unused or expired Assurans must be disposed of in accordance with local/regional/national regulations for pharmaceutical waste. Disposal via wastewater or household trash is generally prohibited unless a drug take-back program specifically authorizes it. Consult a pharmacist for proper disposal if local guidelines are unclear.